What it is — A triple-receptor research compound activating GIP, GLP-1, and glucagon receptors simultaneously — currently the most-watched molecule in metabolic science. Why it's studied — GLP-3-RT extends the incretin research framework by adding glucagon receptor activity, opening energy expenditure into the mechanism alongside the established incretin pathways. It's the first triple agonist to reach mid-stage research and represents the leading edge of the category. Key research findings

• Most significant metabolic marker improvements ever recorded in the incretin class (Phase 2 research)

• Documented improvements in HbA1c, lipid profile, and hepatic fat markers

• Triple-receptor mechanism unique among research compounds in current development